By analysing tumour and blood samples from men with prostate cancer, we further show that GALNT7 levels remain high in castrate resistant prostate cancer, thus suggesting GALNT7 is increased during both the development of prostate cancer and the progression to relapsed treatment resistant disease. Here, GALNT7 is linked to neoplasm.